共 464 条
[21]
Seymour M(2004)Antiangiogenic scheduling of lower dose cancer chemotherapy Nat Rev Cancer 4 423-36
[22]
Homerin M(2001)Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial Cancer J 7 427-11
[23]
Hmissi A(1992)A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer J Clin Oncol 10 904-43
[24]
Cassidy J(2005)Pulmonary metastases of the Lewis lung tumor—cell kinetics and response to cyclophosphamide at different sizes Br J Cancer 93 1236-36
[25]
Giacchetti S(1977)The genetic origin of drug resistance in neoplasms: implications for systemic therapy Cancer Treat Rep 61 29-53
[26]
Perpoint B(1984)Advances in the treatment of metastatic colorectal cancer Cancer Res 44 3643-8
[27]
Zidani R(2005)A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer Oncologist 10 40-30
[28]
Le Bail N(2004)FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 23-37
[29]
Faggiuolo R(2004)Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) [abstr 512] J Clin Oncol 22 229-14
[30]
Focan C(2002)Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment Proc Am Soc Clin Oncol 21 29a-2